DCM
RAPT

Dimension Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Dimension Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,313
Closed -$16.6K – 105
2024
Q4 		$16.6K Buy
+1,313
New +$16.7K ﹤0.01% 110

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Dimension Capital Management's RAPT Position: Q1 2025 in Review

Dimension Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 1,313 shares — an estimated $16.6K sold.

Dimension Capital Management first reported a position in RAPT in Q4 2024 and held it in 1 quarter. The position peaked at $16.6K in Q4 2024. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Dimension Capital Management reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Dimension Capital Management sold 1,313 RAPT Therapeutics shares in Q1 2025, an estimated $16.6K.
  • Dimension Capital Management first reported a position in RAPT Therapeutics in Q4 2024 and held it in 1 quarter.
  • Dimension Capital Management's RAPT Therapeutics position peaked at $16.6K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Dimension Capital Management's 13F filing for Q1 2025, filed 15 May 2025.